Table 1 Clinicopathological characteristics of ccRCC patients with differential NUF2 expression
From: NUF2 is correlated with a poor prognosis and immune infiltration in clear cell renal cell carcinoma
Characteristic | Low expression of NUF2(n = 265) | High expression of NUF2(n = 265) | p |
|---|---|---|---|
Age, n (%) | Â | Â | 0.259 |
<=60 | 125 (23.6%) | 139 (26.2%) | Â |
> 60 | 140 (26.4%) | 126 (23.8%) |  |
Gender, n (%) | Â | Â | 0.084 |
Female | 103 (19.4%) | 83 (15.7%) | Â |
Male | 162 (30.6%) | 182 (34.3%) | Â |
Race, n (%) | Â | Â | 0.284 |
Asian | 3 (0.6%) | 5 (1%) | Â |
Black or African American | 33 (6.3%) | 23 (4.4%) | Â |
White | 225 (43%) | 234 (44.7%) | Â |
T stage, n (%) |  |  | < 0.001 |
T1 | 155 (29.2%) | 116 (21.9%) | Â |
T2 | 35 (6.6%) | 34 (6.4%) | Â |
T3 | 74 (14%) | 105 (19.8%) | Â |
T4 | 1 (0.2%) | 10 (1.9%) | Â |
N stage, n (%) | Â | Â | 0.032 |
N0 | 119 (46.7%) | 120 (47.1%) | Â |
N1 | 3 (1.2%) | 13 (5.1%) | Â |
M stage, n (%) |  |  | < 0.001 |
M0 | 225 (45.2%) | 195 (39.2%) | Â |
M1 | 23 (4.6%) | 55 (11%) | Â |
Pathologic stage, n (%) |  |  | < 0.001 |
Stage I | 151 (28.7%) | 114 (21.6%) | Â |
Stage II | 31 (5.9%) | 26 (4.9%) | Â |
Stage III | 58 (11%) | 65 (12.3%) | Â |
Stage IV | 25 (4.7%) | 57 (10.8%) | Â |
Histologic grade, n (%) | Â | Â | 0.042 |
G1 | 10 (1.9%) | 4 (0.8%) | Â |
G2 | 124 (23.8%) | 103 (19.7%) | Â |
G3 | 97 (18.6%) | 109 (20.9%) | Â |
G4 | 30 (5.7%) | 45 (8.6%) | Â |